Cardio IQ® LPA Aspirin Genotype
Also known as: CardioIQ®, LPA Aspirin Genotype, Apolipoprotein(a) gene polymorphism, LPA 4399Met genotype
Use
This test identifies individuals who are at risk of having elevated plasma lipoprotein (a) [Lp(a)] and increased cardiovascular risk, which may be reduced by low‑dose aspirin therapy.
Special Instructions
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA. Multiple (up to 8) cardiovascular‑related genetic tests can be performed on a single specimen. A second EDTA (lavender‑top) tube is required if non‑genetic tests are simultaneously ordered that require an EDTA (lavender‑top) tube. For whole blood samples, follow normal phlebotomy procedures.
Limitations
Not provided.
Methodology
PCR‑based (PCR)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
2 mL
Container
EDTA (lavender‑top) tube
Collection Instructions
Follow normal phlebotomy procedures
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 days |
| Refrigerated | 8 days |
| Frozen | 30 days |